The Regenix Group's pharmaceutical heritage takes shape across pharma, retail and diagnostics.
The parent pharmaceutical company is incorporated as a Public Limited (Unlisted) Company, promoted by a network of 2,500+ medical doctors.
Retail pharmacy operations begin, scaling to 100+ stores across India under integrated pharmacy-management software.
NABL-accredited central laboratory for genetics, molecular biology, allergy, new-born screening, biochemistry and microbiology. Scales to 35+ diagnostic centres across Tamil Nadu and Kerala.
The biotech and biosimilar division is founded at MEPZ-SEZ Chennai, and the facility earns WHO-GMP certification.
The biotech and biosimilar division of the Regenix Group is incorporated. Single mandate — manufacture biosimilars for global access from one integrated sterile facility.
30,000 sq ft sterile manufacturing facility achieves WHO-GMP certification, enabling international tender participation and reference-market filings.
Four CDSCO-approved biosimilars reach the Indian market — establishing a full-spectrum diabetes franchise across short-acting, long-acting, biphasic and GLP-1 therapy.
First Regenix biosimilar reaches the Indian market. Long-acting basal insulin in disposable pen and cartridge formats — manufactured in-house at the MEPZ-SEZ Chennai facility.
GLP-1 receptor agonist for type-2 diabetes and weight management joins the portfolio, expanding Regenix's diabetes franchise beyond insulins into incretin-based therapy.
Marketing Authorisations granted for Human Insulin (Regular) and Biphasic Insulin (30/70). With these two additions, Regenix holds four CDSCO approvals across the full diabetes spectrum — short-acting, long-acting, biphasic and GLP-1.
Active expansion across SE Asia, Africa, Latin America and Middle East & CIS — building toward 120+ countries targeted by 2028.
Partnerships, licensing engagements and tender qualifications across 120+ markets — built on the same vertical integration that's powered Regenix from the start.
Partner with us →